PFG
BCLI

Piershale Financial Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Piershale Financial Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$206 Hold
7
– – ﹤0.01% 269
2023
Q1 		$330 Buy
+7
New +$203 ﹤0.01% 293

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Piershale Financial Group's BCLI Position: Q2 2023 in Review

Piershale Financial Group held its BRAINSTORM CELL THERAPUTC (BCLI) position steady in Q2 2023 at 7 shares worth $206. The position accounts for ﹤0.01% of the portfolio, ranked #269.

Piershale Financial Group first reported a position in BCLI in Q1 2023 and has held it in 2 quarters since. The position peaked at $330 in Q1 2023. 58 funds tracked by Wall St. Rank hold BCLI as of Q2 2023.

  • Piershale Financial Group held 7 shares of BRAINSTORM CELL THERAPUTC worth $206 as of Q2 2023.
  • Piershale Financial Group left its BRAINSTORM CELL THERAPUTC share count unchanged in Q2 2023.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of Piershale Financial Group's portfolio in Q2 2023, its #269 holding.
  • Piershale Financial Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2023 and has held it in 2 quarters since.
  • Piershale Financial Group's BRAINSTORM CELL THERAPUTC position peaked at $330 in Q1 2023.
  • 58 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.